ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2218

Pregnancy Outcomes and Placental Findings in Women with IgA Vasculitis: A Case-Control Study

Edgar Iván Mendoza Ríos, María Del Carmen Zamora Medina, Mario Isaac Lumbreras Márquez, Diana Yazmin Copado mendoza, Oralia Alejandra Orozco Guillén, Maria José rodríguez Sibaja, Martha Leticia Palafox Vargas and Sandra Acevedo gallegos, Instituto Nacional de Perinatología, Mexico City, Distrito Federal, Mexico

Meeting: ACR Convergence 2025

Keywords: pregnancy, Vasculitis, Women's health

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2195–2226) Reproductive Issues in Rheumatic Disorders Posters

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: IgA vasculitis (IgA-V) is a systemic vasculitis involving small vessels, most frequently affecting children. There is few information about pregnancy outcomes in women with history of IgA-V and no data regarding placental findings in these pregnancies. The aim of this study is to compare vasculitic, maternal and fetal outcomes, and placental findings in pregnant patients with IgA-V and healthy patients.

Methods: We conducted a retrospective case-control study in a single third level center in Mexico City. We included pregnant women and prior IgA-V diagnosis (cases), with placental histopathology available. Control group included healthy pregnant patients matched by age, number of pregnancies, number of fetuses, BMI and smoking status. Placental findings were categorized per the 2016 Amsterdam Working Group: 1) Maternal vascular malperfusion (MVM), 2) fetal vascular malperfusion (FVM), 3) inflammation/infection, and 4) villitis of unknown etiology.

Results: We analyzed 20 pregnancies in patients with history of IgA vasculitis and 60 matched controls. The median age at IgA-V diagnosis was 12.0 [IQR 7.5, 15.5] years and mean age at gestation was 25.10 ± 4.90 years. During pregnancy two patients (10%) flared, presenting cutaneous manifestations. No differences were observed in hypertensive disorders of pregnancy (5% vs 6.7%; p=0.99), gestational diabetes (0% vs 3.3%; p=0.99), preterm delivery (mean gestational age at birth 38.83 ± 0.99 vs 38.49 ± 2.16; p=0.50), fetal growth restriction (15% vs 5%; p=0.16), stillbirth (0% vs 1.7%; p=0.99), NICU admission (5% vs 6.8%; p=0.99) and perinatal death (5% vs 1.7%; p=0.44). Placental weight averaged 443.62 ± 85.61 grams in IgA-V group, similar to control group (p=0.45). Maternal vascular malperfusión (45% vs 36.7%; p=0.599) and fetal vascular malperfusion (40% vs 23%; p=0.16) were the main placental findings in both groups.

Conclusion: Women with a history of IgA-V have favourable maternal and fetal outcomes, similar to the healthy population matched by age. Placental findings, such as MVM and FVM, were not more frequent in patients with IgA-V.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: E. Mendoza Ríos: None; M. Zamora Medina: None; M. Lumbreras Márquez: None; D. Copado mendoza: None; O. Orozco Guillén: None; M. rodríguez Sibaja: None; M. Palafox Vargas: None; S. Acevedo gallegos: None.

To cite this abstract in AMA style:

Mendoza Ríos E, Zamora Medina M, Lumbreras Márquez M, Copado mendoza D, Orozco Guillén O, rodríguez Sibaja M, Palafox Vargas M, Acevedo gallegos S. Pregnancy Outcomes and Placental Findings in Women with IgA Vasculitis: A Case-Control Study [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/pregnancy-outcomes-and-placental-findings-in-women-with-iga-vasculitis-a-case-control-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pregnancy-outcomes-and-placental-findings-in-women-with-iga-vasculitis-a-case-control-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology